This pipeline computes the correlation between cancer subtypes identified by different molecular patterns and selected clinical features.
Testing the association between subtypes identified by 7 different clustering approaches and 5 clinical features across 430 patients, 28 significant findings detected with P value < 0.05.
-
CNMF clustering analysis on array-based mRNA expression data identified 4 subtypes that correlate to 'AGE', 'HISTOLOGICAL.TYPE', 'RADIATIONS.RADIATION.REGIMENINDICATION', and 'NEOADJUVANT.THERAPY'.
-
Consensus hierarchical clustering analysis on array-based mRNA expression data identified 3 subtypes that correlate to 'HISTOLOGICAL.TYPE' and 'NEOADJUVANT.THERAPY'.
-
3 subtypes identified in current cancer cohort by 'METHLYATION CNMF'. These subtypes correlate to 'Time to Death', 'AGE', 'HISTOLOGICAL.TYPE', and 'NEOADJUVANT.THERAPY'.
-
CNMF clustering analysis on sequencing-based mRNA expression data identified 3 subtypes that correlate to 'Time to Death', 'AGE', 'HISTOLOGICAL.TYPE', 'RADIATIONS.RADIATION.REGIMENINDICATION', and 'NEOADJUVANT.THERAPY'.
-
Consensus hierarchical clustering analysis on sequencing-based mRNA expression data identified 3 subtypes that correlate to 'Time to Death', 'AGE', 'HISTOLOGICAL.TYPE', 'RADIATIONS.RADIATION.REGIMENINDICATION', and 'NEOADJUVANT.THERAPY'.
-
CNMF clustering analysis on sequencing-based miR expression data identified 3 subtypes that correlate to 'Time to Death', 'AGE', 'HISTOLOGICAL.TYPE', and 'NEOADJUVANT.THERAPY'.
-
Consensus hierarchical clustering analysis on sequencing-based miR expression data identified 3 subtypes that correlate to 'AGE', 'HISTOLOGICAL.TYPE', 'RADIATIONS.RADIATION.REGIMENINDICATION', and 'NEOADJUVANT.THERAPY'.
Clinical Features |
Time to Death |
AGE |
HISTOLOGICAL TYPE |
RADIATIONS RADIATION REGIMENINDICATION |
NEOADJUVANT THERAPY |
Statistical Tests | logrank test | ANOVA | Chi-square test | Fisher's exact test | Fisher's exact test |
mRNA CNMF subtypes | 0.53 | 0.0107 | 0.000456 | 0.0317 | 0.0124 |
mRNA cHierClus subtypes | 0.73 | 0.0598 | 0.00134 | 0.0666 | 0.0114 |
METHLYATION CNMF | 0.00798 | 0.0123 | 4.28e-17 | 0.0786 | 0.0132 |
RNAseq CNMF subtypes | 0.00873 | 0.00104 | 8.73e-18 | 0.0148 | 0.000242 |
RNAseq cHierClus subtypes | 0.00985 | 0.00202 | 8.69e-18 | 0.0325 | 1.45e-05 |
MIRseq CNMF subtypes | 0.00602 | 0.000193 | 5.4e-20 | 0.0958 | 0.00481 |
MIRseq cHierClus subtypes | 0.0652 | 3.03e-05 | 1.14e-13 | 0.0303 | 0.0281 |
Cluster Labels | 1 | 2 | 3 | 4 |
---|---|---|---|---|
Number of samples | 13 | 19 | 14 | 8 |
P value = 0.53 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 54 | 7 | 6.0 - 133.2 (35.4) |
subtype1 | 13 | 2 | 9.0 - 133.2 (39.0) |
subtype2 | 19 | 3 | 6.0 - 113.2 (37.7) |
subtype3 | 14 | 1 | 8.6 - 89.3 (30.9) |
subtype4 | 8 | 1 | 6.4 - 65.5 (22.9) |
P value = 0.0107 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 54 | 62.9 (11.8) |
subtype1 | 13 | 65.1 (12.0) |
subtype2 | 19 | 68.4 (9.1) |
subtype3 | 14 | 58.2 (11.0) |
subtype4 | 8 | 54.8 (12.9) |
P value = 0.000456 (Chi-square test)
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 41 | 1 | 12 |
subtype1 | 12 | 0 | 1 |
subtype2 | 8 | 0 | 11 |
subtype3 | 13 | 1 | 0 |
subtype4 | 8 | 0 | 0 |
P value = 0.0317 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 25 | 29 |
subtype1 | 7 | 6 |
subtype2 | 13 | 6 |
subtype3 | 3 | 11 |
subtype4 | 2 | 6 |
P value = 0.0124 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 18 | 36 |
subtype1 | 6 | 7 |
subtype2 | 10 | 9 |
subtype3 | 2 | 12 |
subtype4 | 0 | 8 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 20 | 15 | 19 |
P value = 0.73 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 54 | 7 | 6.0 - 133.2 (35.4) |
subtype1 | 20 | 2 | 6.4 - 89.3 (29.8) |
subtype2 | 15 | 2 | 9.0 - 133.2 (39.0) |
subtype3 | 19 | 3 | 6.0 - 113.2 (37.7) |
P value = 0.0598 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 54 | 62.9 (11.8) |
subtype1 | 20 | 58.2 (13.3) |
subtype2 | 15 | 64.0 (10.6) |
subtype3 | 19 | 67.1 (9.9) |
P value = 0.00134 (Chi-square test)
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 41 | 1 | 12 |
subtype1 | 19 | 1 | 0 |
subtype2 | 13 | 0 | 2 |
subtype3 | 9 | 0 | 10 |
P value = 0.0666 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 25 | 29 |
subtype1 | 5 | 15 |
subtype2 | 9 | 6 |
subtype3 | 11 | 8 |
P value = 0.0114 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 18 | 36 |
subtype1 | 2 | 18 |
subtype2 | 6 | 9 |
subtype3 | 10 | 9 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 119 | 71 | 123 |
P value = 0.00798 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 309 | 30 | 0.0 - 187.1 (12.8) |
subtype1 | 117 | 18 | 0.0 - 187.1 (11.5) |
subtype2 | 71 | 4 | 0.0 - 92.0 (17.5) |
subtype3 | 121 | 8 | 0.1 - 173.6 (13.0) |
P value = 0.0123 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 312 | 63.5 (11.1) |
subtype1 | 118 | 65.8 (10.0) |
subtype2 | 71 | 63.0 (12.9) |
subtype3 | 123 | 61.6 (10.8) |
P value = 4.28e-17 (Chi-square test)
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 1) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 2) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 3) | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|---|---|---|
ALL | 229 | 6 | 1 | 3 | 16 | 58 |
subtype1 | 54 | 1 | 0 | 1 | 13 | 50 |
subtype2 | 58 | 2 | 1 | 0 | 2 | 8 |
subtype3 | 117 | 3 | 0 | 2 | 1 | 0 |
P value = 0.0786 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 79 | 234 |
subtype1 | 32 | 87 |
subtype2 | 11 | 60 |
subtype3 | 36 | 87 |
P value = 0.0132 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 70 | 243 |
subtype1 | 37 | 82 |
subtype2 | 10 | 61 |
subtype3 | 23 | 100 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 96 | 83 | 87 |
P value = 0.00873 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 266 | 20 | 0.0 - 173.6 (20.2) |
subtype1 | 96 | 13 | 0.5 - 133.2 (17.8) |
subtype2 | 83 | 2 | 0.6 - 101.1 (21.4) |
subtype3 | 87 | 5 | 0.0 - 173.6 (22.6) |
P value = 0.00104 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 266 | 63.1 (10.8) |
subtype1 | 96 | 66.2 (10.4) |
subtype2 | 83 | 62.4 (10.6) |
subtype3 | 87 | 60.4 (10.7) |
P value = 8.73e-18 (Chi-square test)
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 1 OR 2) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 1) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 2) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 3) | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|---|---|---|---|
ALL | 205 | 3 | 4 | 1 | 5 | 7 | 41 |
subtype1 | 45 | 0 | 0 | 0 | 4 | 6 | 41 |
subtype2 | 78 | 2 | 2 | 0 | 0 | 1 | 0 |
subtype3 | 82 | 1 | 2 | 1 | 1 | 0 | 0 |
P value = 0.0148 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 99 | 167 |
subtype1 | 44 | 52 |
subtype2 | 21 | 62 |
subtype3 | 34 | 53 |
P value = 0.000242 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 83 | 183 |
subtype1 | 45 | 51 |
subtype2 | 19 | 64 |
subtype3 | 19 | 68 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 96 | 82 | 88 |
P value = 0.00985 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 266 | 20 | 0.0 - 173.6 (20.2) |
subtype1 | 96 | 12 | 0.6 - 133.2 (17.7) |
subtype2 | 82 | 1 | 0.6 - 101.1 (22.7) |
subtype3 | 88 | 7 | 0.0 - 173.6 (22.5) |
P value = 0.00202 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 266 | 63.1 (10.8) |
subtype1 | 96 | 66.0 (10.4) |
subtype2 | 82 | 62.5 (10.4) |
subtype3 | 88 | 60.5 (11.0) |
P value = 8.69e-18 (Chi-square test)
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 1 OR 2) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 1) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 2) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 3) | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|---|---|---|---|
ALL | 205 | 3 | 4 | 1 | 5 | 7 | 41 |
subtype1 | 45 | 0 | 0 | 0 | 4 | 6 | 41 |
subtype2 | 77 | 2 | 2 | 0 | 0 | 1 | 0 |
subtype3 | 83 | 1 | 2 | 1 | 1 | 0 | 0 |
P value = 0.0325 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 99 | 167 |
subtype1 | 44 | 52 |
subtype2 | 22 | 60 |
subtype3 | 33 | 55 |
P value = 1.45e-05 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 83 | 183 |
subtype1 | 47 | 49 |
subtype2 | 15 | 67 |
subtype3 | 21 | 67 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 147 | 124 | 101 |
P value = 0.00602 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 370 | 30 | 0.0 - 187.1 (17.4) |
subtype1 | 146 | 18 | 0.0 - 187.1 (15.5) |
subtype2 | 123 | 3 | 0.1 - 101.1 (17.3) |
subtype3 | 101 | 9 | 0.5 - 173.6 (23.3) |
P value = 0.000193 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 372 | 63.2 (11.2) |
subtype1 | 147 | 65.9 (10.6) |
subtype2 | 124 | 62.5 (11.6) |
subtype3 | 101 | 60.1 (10.8) |
P value = 5.4e-20 (Chi-square test)
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 1 OR 2) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 1) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 2) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 3) | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|---|---|---|---|
ALL | 284 | 3 | 9 | 2 | 7 | 13 | 54 |
subtype1 | 77 | 1 | 1 | 0 | 4 | 11 | 53 |
subtype2 | 117 | 2 | 3 | 0 | 1 | 1 | 0 |
subtype3 | 90 | 0 | 5 | 2 | 2 | 1 | 1 |
P value = 0.0958 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 123 | 249 |
subtype1 | 58 | 89 |
subtype2 | 34 | 90 |
subtype3 | 31 | 70 |
P value = 0.00481 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 96 | 276 |
subtype1 | 51 | 96 |
subtype2 | 22 | 102 |
subtype3 | 23 | 78 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 114 | 169 | 89 |
P value = 0.0652 (logrank test)
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 370 | 30 | 0.0 - 187.1 (17.4) |
subtype1 | 113 | 4 | 0.1 - 101.1 (17.3) |
subtype2 | 168 | 18 | 0.0 - 187.1 (17.8) |
subtype3 | 89 | 8 | 0.6 - 173.6 (16.8) |
P value = 3.03e-05 (ANOVA)
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 372 | 63.2 (11.2) |
subtype1 | 114 | 63.8 (10.5) |
subtype2 | 169 | 65.2 (10.8) |
subtype3 | 89 | 58.6 (11.7) |
P value = 1.14e-13 (Chi-square test)
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 1 OR 2) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 1) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 2) | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA (GRADE 3) | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|---|---|---|---|
ALL | 284 | 3 | 9 | 2 | 7 | 13 | 54 |
subtype1 | 103 | 2 | 4 | 0 | 1 | 1 | 3 |
subtype2 | 100 | 0 | 2 | 0 | 4 | 12 | 51 |
subtype3 | 81 | 1 | 3 | 2 | 2 | 0 | 0 |
P value = 0.0303 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 123 | 249 |
subtype1 | 31 | 83 |
subtype2 | 68 | 101 |
subtype3 | 24 | 65 |
P value = 0.0281 (Fisher's exact test)
nPatients | NO | YES |
---|---|---|
ALL | 96 | 276 |
subtype1 | 23 | 91 |
subtype2 | 55 | 114 |
subtype3 | 18 | 71 |
-
Cluster data file = UCEC.mergedcluster.txt
-
Clinical data file = UCEC.clin.merged.picked.txt
-
Number of patients = 430
-
Number of clustering approaches = 7
-
Number of selected clinical features = 5
-
Exclude small clusters that include fewer than K patients, K = 3
consensus non-negative matrix factorization clustering approach (Brunet et al. 2004)
Resampling-based clustering method (Monti et al. 2003)
For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R
For continuous numerical clinical features, one-way analysis of variance (Howell 2002) was applied to compare the clinical values between tumor subtypes using 'anova' function in R
For multi-class clinical features (nominal or ordinal), Chi-square tests (Greenwood and Nikulin 1996) were used to estimate the P values using the 'chisq.test' function in R
For binary clinical features, two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.